. 2022 Apr 26;11(2):459–476. doi: 10.1007/s40122-022-00381-1

Table 2.

Summary of in-human studies using implant-free SRS for chronic pain

References	PN	Design	Target	Indication	FU	Outcome	SAE/AE
Non-invasive lesioning (non-reversible)
Franzini et al. [55]	8	PT	SRS Central lateral thalamotomy	TDP	24 months	3.9 points relief in VAS/recurrence 2 patents after 36 months	None
				BPI
				CPSP
				PHN
Young et al. [59]	10	PT	SRS Intralaminar nuclei, the lateral portion of the medial dorsal nucleus and CmPf Unilateral lesion: 9 patents Bilateral lesion: 1 patent	SD	NA	Excellent: 3	None
				PHN		Acceptable: 4
				SCI		Failure: 3
				TP
				AD
				CPSP
Young et al. [62]	20	PT	SRS/thalamotomy	Different origin	22 months	Excellent/good pain relief	1 death radiation necrosis
Young et al. [62]	20	PT	140–180 Gy	Different origin	22 months	(Not specified)	1 death radiation necrosis
Young et al. [62]	19	PT	SRS	Different origin	12 months	27% pain free	Not reported
Young et al. [62]	19	PT	Intralaminar, mediodorsal, centromedian and parafascicular nuclei	Different origin	12 months	33% > 50% pain relief	Not reported
Steiner et al. [60]	NA	PT	SRS	CCP	NA	Significant pain relief in 35%	None
Steiner et al. [60]	NA	PT	Medial thalamotomy	CCP	NA	Significant pain relief in 35%	None
Frighetto et al. [58]	3	PT	SRS	CPSP	NA	Significant pain relief	None
Frighetto et al. [58]	3	PT	Medial thalamotomy	CCP	NA	Recurrence after 4 months	None

SRS stereotactic radiosurgery, PT pilot study, RCT randomized controlled trial, CR case report, VPL nucleus ventrolateralis of the thalamus, CPSP chronic post-stroke pain, FU follow-up, SAE/AE serious adverse event, ICH intracranial haemorrhage, NP neuropathic pain, TN trigeminal neuralgia, CCP chronic cancer pain, TDP trigeminal deafferentation pain, AD anesthesia dolorosa, TP thalamic pain, SCI spinal cord injury, PHN postherpatic neuralgia, SD spinal disorders, BPI plexus brachialis injury, NA not applicable